PATENT

The the certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, Washington, DC 20231.

July 10, 200

Date

Linda Povinelli

#22

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

B. Brett Finlay et al.

Application No.

09/189,415

Filed

: November 10, 1998

For

HOST RECEPTOR FOR PATHOGENIC BACTERIA

Examiner

S. Devi

RECEIVED

Art Unit

1645

JUL 1 7 2001

Docket No.

482112.402

. -/

Date

July 10, 2001

OFFICE OF PETITIONS

Commissioner for Patents Washington, DC 20231

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Commissioner for Patents:

In response to the Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed June 27, 2001, Applicants submit the following:

- (1) Declaration regarding Sequence Listing;
- (2) Paper copy of Sequence Listing (11 pages);
- (3) Computer Readable Form of Sequence Listing; and

(4) Copy of Notice to Comply.

The enclosed Sequence Listing includes no new material and complies with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. Applicants respectfully submit that this application is now in compliance with 37 C.F.R. §§ 1.821-1.825 and WIPO Standard 25.



Respectfully submitted,

Seed Intellectual Property Law Group PLLC

Jeffrey C. Pepe, Ph.D!
Registration No. 46,985

Phone: (206) 622-4900 Fax: (206) 682-6031

JCP:lmp

193943

RECEIVED

JUL 1 7 2001

OFFICE OF PETITIONS

| lease type a plus sign (+) inside this box -> +

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

15	pond to a collection of information unless	it displays a valid OMB control number.								
	Application Number	09/189,415								
	Filing Date	November 10, 1998								
	First Named Inventor	B. Brett Finlay								
	Group Art Unit	1645								
	Examiner Name	S. Devi								
	Attorney Docket No.	482112.402								

	EN	NCLOSURES (check all that app	oly)									
Fee Transmittal F Fee Attached Amendment/Res After Final Affidavits/ded Extension of Time Express Abandor Request Information Disclestatement; Form Cited References Certified Copy of Document(s) Response to Missunder 37 C.F.R. Response to Missunder 37 C.F.R.	d ponse claration(s) se Request nment cosure PTO-1449 sering Parts 1.52 or 1.53 sing	Assignment Papers (for an Application) Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition TO REVIVE Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration re: Sequence Listing Statement under 37 CFR 3.73(b) Terminal Disclaimer Small Entity Statement Request for Refund	□ CD(s), Number of CD(s) □ After Allowance Communication to Group □ Appeal Communication to Board of Appeals and Interferences □ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) □ Proprietary Information □ Status Letter ☒ Return Receipt Postcard ☒ Additional Enclosure(s) (please identify below): Response to Notice to Comply; Paper Copy of Sequence Listing; CRF of Sequence Listing (11 pages); and Copy of Notice to Comply with Sequence Requirements									
												
		RE OF APPLICANT, ATTORNEY,	OR AGENT									
Individual Name J	Jeffrey C. Pepe	e, Ph.D.	00500 PATENT TRADEMARK OFFICE									
Signature	Juh	Who -										
Date	- 11	2/10/01	·.									
		7/10/01										
		CERTIFICATE OF MAILING										

Date	7/10	0/01												
	,													
CERTIFICATE OF MAILING														
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on the date specified below.														
Typed or printed na	ame Linda M. F	Povinelli		D										
Signature	W.	Wasil	Date: 7(00)	RECEIVE										
193937 [12/19/00]				JUL 1 7 2001										

	PΊ	TO/SB/17	(11-00
Approved for use through	10/31/2002.	OMB 06	51-003

JUL 1 3 ZOUT Z

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) | 620.00


	Complete if Known
Application Number	09/189,415
Filing Date	November 10, 1998
First Named Inventor	B. Brett Finlay
Examiner Name	S. Devi
Group Art Unit	1645
Attorney Docket No.	482112.402

METHOD OF PAYMENT	FEE CALCULATION (continued)										
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:	Large	3. ADDITIONAL FEES Large Entity Small									
Deposit	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description Fee Paid						
Account 19-1090 Number	105	130	205	65	Surcharge - late filing fee or oath	٦					
Deposit	127	50	227	25	Surcharge - late provisional filing fee or cover sheet.						
Account Name Seed Intellectual Property Law Group PLLC	139	130	139	130	Non-English specification						
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	147	2,520	147	2,520	For filing a request for ex parte reexamination						
and credit any overpayment to Deposit Account Number above. Applicant claims small entity status. See 37 CFR 1.27	112	920*	112	920*	Requesting publication of SIR prior to Examiner action						
	113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action]					
	115	110	215	55	Extension for reply within first month]					
│ │ │ │ │ │ │ Credit card │ │ Money │ │ Other Order	116	390	216	195	Extension for reply within second month	7					
FEE CALCULATION	117	890	217	445	Extension for reply within third month]					
	118	1,390	218	695	Extension for reply within fourth	7					
BASIC FILING FEE Large Entity	128	1,890	228	945	month Extension for reply within fifth month	-					
Fee Fee Fee Fee Description	119	310	219	155	Notice of Appeal	1					
Code (\$) Code (\$) Fee Paid	120	310	220	155	Filing a brief in support of an appeal	1					
106 320 206 160 Design filing fee	121	270	221	135	Request for oral hearing]					
107 490 207 245 Plant filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding						
108	140	110	240	55	Petition to revive – unavoidable]					
	141	1,240	241	620	Petition to revive – unintentional 620]					
SUBTOTAL (1) (\$)	142	1,240	242	620	Utility issue fee (or reissue)						
2. EXTRA CLAIM FEES	143	440	243	220	Design issue fee						
Extra Fee from Fee Claims below Paid	144	600	244	300	Plant issue fee	_					
Total	122	130	122	130	Petitions to the Commissioner	4					
Claims X = X	123	130	123	130	Petitions related to provisional applications						
Claims	126	180	126	180	Submission of Information Disclosure Stmt						
Multiple Dependent Large Entity Small Entity	581	40	581	40	Recording each patent assignment per property (times number of properties)						
Fee Fee Fee Fee Description Code (\$) Code (\$)	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))	1					
103 18 203 9 Claims in excess of 20 102 80 202 40 Independent claims in excess of 3	149	710	249	355	For each additional invention to be examined (37 CFR § 1.129(b))	1					
104 270 204 135 Multiple dependent claim, if not paid	179	710	279	355	Request for Continued Examination (RCE)	1					
original patent	169	900	169	900	Request for expedited examination of a design application	1					
110 18 210 9 Nessate claims in excess of 20 and over original patent	Other fee	(specify				_					
SUBTOTAL (2) (\$)	*Reduce	d by Bas	ic Filing	Fee Pa	sid SUBTOTAL (3) (\$) 620						
**or number previously paid, if greater; For Reissues, see above											
SUBMITTED BY					1 (1 1 1 1 1 1 1 1 1						
Name (Print/Type) Jeffrey C. Pepe	Registration Attorney/A		46,9	85							
Firm Name/ Address					00500						
1	Date	7/10	101		——— 00500 PATENT TRADEMARK OFFICE						
168585			<u> </u>		I						

RECEIVED

JUL 1 7 2001

RAWSEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number:

09/189415

Art Unit / Team No. :

164/

Date Processed by STIC:

3/10/2000

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

MARK SPENCER 703-308-4212

RECEIVED

JUL 1 7 2001

OFFICE OF PETITIONS

Application : 09/189,415

NOTICE O COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTISE SOURCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	1.	. This application clearly fails to comply with the requirements of 37 attention is directed to these regulations, published at 1114 OG 29 18230, May 1, 1990.	C.F.R. 1.821-1.8 , May 15, 1990 a	25. Applicant's and at 55 FR											
	2.	This application does not contain, as a separate part of the disclos Listing as required by 37 C.F.R. 1.821(c).	ure on paper cop	oy, a "Sequence											
	3.	a. A copy of the "Sequence Listing" in computer readable form has no 37 C.F.R. 1.821(e).	ot been submitte	d as required by											
X	4.	. A copy of the "Sequence Listing" in computer readable form has be content of the computer readable form does not comply with the re and/or 1.823, as indicated on the attached copy of the marked -up	quirements of 37	C.F.R. 1.822											
	 The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). 														
	6.	. The paper copy of the "Sequence Listing" is not the same as the co "Sequence Listing" as required by 37 C.F.R. 1.821(e).	omputer readable	e from of the											
	7.	Other:													
Ар	ilq	icant Must Provide:													
X		n initial or substitute computer readable form (CRF) copy of the "Sec	quence Listing".												
X	Ar int	n initial or substitute paper copy of the "Sequence Listing", as well as to the specification.	s an amendment	directing its entry											
	ap	statement that the content of the paper and computer readable copiceplicable, include no new matter, as required by 37 C.F.R. 1.821(e) of 825(b) or 1.825(d).	ies are the same or 1.821(f) or 1.8	and, where 21(g) or											
For	qι	uestions regarding compliance to these requirements, p	lease contact	:											
		ules Interpretation, call (703) 308-4216		RECEIVED											
For Dat	Cl	RF Submission Help, call (703) 308-4212		JUL 1 7 2001											
ı⁻alı		itIn Software Program Support (SIRA) echnical Assistance703-287-	0200												
	Τ.	o Durchago Detantla Coffuera 702 202 2		OFFICE OF PETITIONS											

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE

ERROR DETECTED SUGGESTED CORRECTION

SERIAL NUMBER: 09/189, 415

ATTN	: NEW RULES CASES: I	PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE
1	Wrapped Nucleics	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".
		riease aujust your right margin to .5, as uns will prevent wrapping .
2	Wrapped Aminos	The amino acid number/text at the end of each line "wrapped" down to the next line.
		This may occur if your file was retrieved in a word processor after creating it.
		Please adjust your right margin to .3, as this will prevent "wrapping".
.3	Incorrect Line Length	The rules require that a line not exceed 72 characters in length. This includes spaces.
4	Misaligned Amino Acid	The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs
	Numbering	between the numbering. It is recommended to delete any tabs and use spacing between the numbers.
5	Non-ASCII	This file was not saved in ASCII (DOS) text, as required by the Sequence Rules.
	•	Please ensure your subsequent submission is saved in ASCII text so that it can be processed.
6	Variable Length	Sequence(s) contain n's or Xaa's which represented more than one residue.
<u> </u>	Tanasio Longui	As per the rules, each n or Xaa can only represent a single residue.
		Please present the maximum number of each residue having variable length and
	•	indicate in the (ix) feature section that some may be missing.
7	Patentin ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid
′ —	ratellilli vel. 2.0 bug	sequence(s) Normally, Patentin would automatically generate this section from the
		previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section
		to the subsequent amino acid sequence.
0	Chinned Convenee	Company (a)
8	Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please use the following format for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X:
	(OLD NOLLS)	(i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS")
		(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X:
		This sequence is intentionally skipped
		Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).
9	Skipped Sequences	Sequence(s) missing. If intentional, please use the following format for each skipped sequence.
	(NEW RULES)	<210> sequence id number
	•	<400> sequence id number
1		000
, U	Use of n's or Xaa's	Use of n's and/or Xaa's have been detected in the Sequence Listing.
	(NEW RULES)	Use of <220> to <223> is MANDATORY if n's or Xaa's are present.
	·	In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa repre
1	Use of <213>Organism	Sequence(s) are missing this mandatory field or its response.
	(NEW RULES)	Sequence(s) are missing this mandatory field or its response. JUL 1 7 2001
2	Use of <220>Feature	Sequence(s) are missing the <220>Feature and associated headings.
	(NEW RULES)	Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown"
	,,	Please explain source of genetic material in <220> to <223> section.
		(See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)
, 3	Patentin ver. 2.0 "bug"	Please do not use "Copy to Disk" function of Patentin version 2.0. This causes a corrupted
	. atomiti ver. z.u bug	file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing).
	was me	Instead, please use "File Manager" or any other means to copy file to floppy disk.
	-274	AKS Biotechnology Systems Branch- 5/15/99

1641

PAGE: 1 RAW SEQUENCE LISTING
PATENT APPLICATION US/09/189,415

44

DATE: 03/10/2000 TIME: 15:42:36

Input Set: I189415.RAW

This Raw Listing contains the General Information Section and up to first 5 pages.

```
Does Not Comply
                                                       Corrected Diskette Needed
     <110> APPLICANT: Finlay, Brett B
 2
           Kenny, Brendan
                                                                      p. 2
 3
          DeVinney, Rebekah
           Stein, Markus
 4
     <120> TITLE OF INVENTION: HOST RECEPTOR FOR PATHOGENIC BACTERIA
 5
    <130> FILE REFERENCE: 07422/013001
 6
 7
    <140> CURRENT APPLICATION NUMBER: US/09/189,415
    <141> CURRENT FILING DATE: 1998-11-10
 8
                                                                        RECEIVED
 9
    <150> EARLIER APPLICATION NUMBER: 60/065,130
    <151> EARLIER FILING DATE: 1997-11-12
10
                                                                        JUL 1 7 2001
    <160> NUMBER OF SEQ ID NOS: 9
11
    <170> SOFTWARE: PatentIn Ver. 2.0
12
                                                                      OFFICE OF PETITIONS
    <210> SEO ID NO 1
13
    <211> LENGTH: 1920
14
15
    <212> TYPE: DNA
     <213> ORGANISM: Escherichia coli
16
     <400> SEQUENCE: 1
17
18
           cqqctqcata ccattacqtc ataqtaatat aaaqqaacqt qtcaaatttc taaataaaag 60
          gatatatgta tgcctattgg taaccttggt aataatgtaa atggcaatca tttaattccc 120
19
           cctgcgccgc cactaccttc acaaacagac ggcgcggcac ggggaggaac tggtcatcta 180
20
21
           attageteta caggageatt aggatetegt teattgtttt etceeetgag aaattetatg 240
          gctgattctg tcgattccag agatattcca ggacttccta caaacccatc gaggcttgct 300
22
          gcagctacat ctgagacatg cttgcttgga ggatttgaag ttctccatga taaggggcca 360
23
           cttgatattc tcaatacgca aattggaccc tctgcatttc gtgttgaagt gcaggcagat 420
24
          ggtactcatg ccgctattgg agaaaaaaat ggtttggagg ttagcgttac attaagtcct 480
25
           caagaatgga gcagcttgca atctattgat actgagggta aaaacagatt tgtttttacc 540
26
27
          gggggacgtg gcggtagtgg gcatccgatg gtcactgtcg catcagatat cgcggaagct 600
           cgtacgaaaa tactggccaa attagaccca gacaatcatg gaggacgtca acccaaggac 660
28
29
          gttgatacgc gttctgttgg tgttggcagc gcttcgggaa tagatgatgg cgttgttagc 720
          gaaacccata cttcaacaac aaattccagc gttcgctcag atcctaaatt ctgggtttct 780
30
31
          gteggegeaa ttgetgetgg tttageggga etggeggeaa etggtattge acaggegttg 840
          getttgacae eggaacegga tgateetaca accaeegate etgateagge egcaaatget 900
32
33
          gcagaaagtg caacaaaaga tcagttaacg caagaagcat tcaagaaccc tgagaaccag 960
          aaagttaaca tegatgegaa eggaaatget atteegtetg gggaattaaa agatgatatt 1020
34
35
          gttgagcaaa tagcacaaca agctaaagag gctggtgagg tggccagaca gcaggctgtt 1080
          gaaagcaatg cacaggcgca gcagcgatat gaggatcagc atgccagacg tcaggaggaa 1140
36
37
          ttacagettt categggtat tggttacgge etcageagtg cattgattgt tgctggggga 1200
          attggtgctg gtgtaacgac tgcgctccat agacgaaatc agccggcaga acagacaact 1260
38
39
          actacaacaa cacatacggt agtgcagcaa cagaccggag ggatacccca gcacaaggtg 1320
          gcactgatgc cacaagagcg aagacgcttc tctgatagac gtgattcgca ggggagtgtt 1380
40
41
          gcatcgacac actggtcaga ttcctctagc gaagtggtta atccatatgc tgaagttggg 1440
          ggggctcgga atagtctatc ggctcatcag ccagaagagc atatttatga tgaggtcgct 1500
42
43
          gcagatcctg gttatagcgt tattcagaat ttttcaggga gcggcccagt taccggaagg 1560
```

ttaataggaa ctccagggca aggtatccaa agtacttatg cgcttctggc aaacagcggc 1620

DATE: 03/10/2000 RAW SEQUENCE LISTING PAGE: TIME: 15:42:36

PATENT APPLICATION US/09/189,415

Input Set: I189415.RAW

ggattgcgtt taggtatggg aggattaacg agtggtggcg agacggcagt aagttctgta 1680 aatgccgcac caacgcaggg accagtacgt ttcgtttaaa tatatctgtg agtatttagt 1740 tgaggttggg gtggggtggg ggggcgtttt actagcgtta atgtttcaga gaacaacgtt 1800 gcagcatggg taactcttga acttctgtta ttataatcaa ttaagagaaa ttataatgtc 1860 atcaagatat gaacttttat tagataggtt tgcggaaaaa attggtgttg gatctatttc 1920 <210> SEQ ID NO 2 <211> LENGTH: 549 <212> TYPE: PRT <213> ORGANISM: Escherichia coli <400> SEQUENCE: 2 Met Pro Ile Gly Asn Leu Gly Asn Asn Val Asn Gly Asn His Leu Ile Pro Pro Ala Pro Pro Leu Pro Ser Gln Thr Asp Gly Ala Ala Arg Gly Gly Thr Gly His Leu Ile Ser Ser Thr Gly Ala Leu Gly Ser Arg Ser Leu Phe Ser Pro Leu Arg Asn Ser Met Ala Asp Ser Val Asp Ser Arg Asp Ile Pro Gly Leu Pro Thr Asn Pro Ser Arg Leu Ala Ala Ala Thr Ser Glu Thr Cys Leu Leu Gly Gly Phe Glu Val Leu His Asp Lys Gly Pro Leu Asp Ile Leu Asn Thr Gln Ile Gly Pro Ser Ala Phe Arg Val Glu Val Gln Ala Asp Gly Thr His Ala Ala Ile Gly Glu Lys Asn Gly Leu Glu Val Ser Val Thr Leu Ser Pro Gln Glu Trp Ser Ser Leu Gln Ser Ile Asp Thr Glu Gly Lys Asn Arg Phe Val Phe Thr Gly Gly Arg Gly Gly Ser Gly His Pro Met Val Thr Val Ala Ser Asp Ile Ala Glu Ala Arg Thr Arg Ile Leu Ala Lys Leu Asp Pro Asp Asn His Gly Gly Arg Gln Pro Lys Asp Val Asp Thr Arg Ser Val Gly Val Gly Ser Ala Ser Gly Ile Asp Asp Gly Val Val Ser Glu Thr His Thr Ser Thr Thr 220. Asn Ser Ser Val Arg Ser Asp Pro Lys Phe Trp Val Ser Val Gly Ala Ile Ala Ala Gly Leu Ala Gly Leu Ala Ala Thr Gly Ile Ala Gln Ala Leu Ala Leu Thr Pro Glu Pro Asp Asp Pro Thr Thr Asp Pro Asp Gln Ala Ala Asn Ala Ala Glu Ser Ala Thr Lys Asp Gln Leu Thr Gln Glu Ala Phe Lys Asn Pro Glu Asn Gln Lys Val Asn Ile Asp Ala Asn Gly Asn Ala Ile Pro Ser Gly Glu Lew Xaa Asp Asp Ile Val Glu Gln

sel item 10 turnoung

DATE: 03/10/2000 TIME: 15:42:36 RAW SEQUENCE LISTING PAGE:

PATENT APPLICATION US/09/189,415

Input Set: I189415.RAW

														_				
95		Ile	Ala	${\tt Gln}$	Gln	Ala	Lys	Glu	Ala	Gly	Glu	Val	Ala	Arg	Gln	Gln	Ala	
96						325					330					335		
97	•	Val	Glu	Ser	Asn	Ala	Gln	Ala	Gln	Gln	Arg	Tyr	Glu	Asp	Gln	His	Ala	
98					340					345		_	_		350	_		
99		Arg	Arg	Gln	Glu	Glu	Leu	Gln		Ser	Ser	Gly	Ile		Tyr	Gly	Leu	
100				355					360					365				
101		Ser		Ala	Leu	Ile	Val		GIY	GTĀ	Ile	GIY		GTA	Val	Thr	Thr	
102			370	•	_	_	_	375			~ 1	a1	380		m1	 1	m\	
103			Leu	His	Arg	Arg		GIn	Pro	Ата	GIU		Thr	Thr	Tnr	Thr		
104		385	***	mla an	**- 7	**- 7	390	<i>α</i> 1	71 n	mb~	C1	395	Tla	Dwo	C1 5	uic	400	
105		Thr	HIS	THE	vaı	405	GIII	GIII	GIII	1111	410	GIA	116	PIO	GIII	His 415	пуѕ	
106		17-1	71.	T 011	Mot		Cln	Glu.	λνα	7.20		Dhe	Sar	A en	λνα	Arg	N G D	
107		vaı	Ата	neu	420	PIO	GIII	Giu	Arg	425	Arg	FIIC	Ser	Aap	430	Arg	ASP	
108		Cor	GI n	Gly		17a 1	Δla	Ser	Thr		Trn	Ser	Asn	Ser		Ser	Glu	
109 110		Ser	GIII	435	DCI	Val	AIU	DCI	440		P	501	1101	445	501	001	014	
111		Va 1	Va 1		Pro	Tvr	Δla	Glu		Glv	Glv	Ala	Ara		Ser	Leu	Ser	
112		VUL	450	*****		-1-	•••	455		U -1	1		460					
113		Ala		Gln	Pro	Glu	Glu		Ile	Tyr	Asp	Glu		Ala	Ala	Asp	Pro	
114		465					470			•	_	475				-	480	
115			Tyr	Ser	Val	Ile	Gln	Asn	Fhe	Ser	Gly	Ser	Gly	Pro	Val	Thr	Gly	
116			-			485					490					495		
117		Arg	Leu	Ile	Gly	Thr	Pro	Gly	Gln	Gly	Ile	Gln	Ser	Thr	Tyr	Ala	Leu	
118					500					505					510			
119		Leu	Ala	Asn	Ser	Gly	Gly	Leu	Arg	Leu	Gly	Met	Gly	Gly	Leu	Thr	Ser	
120				515					520					525				
121		Gly	Gly	Glu	Thr	Ala	Val	Ser	Ser	Val	Asn	Ala	Ala	Pro	Thr	Pro	Gly	
122			530					535					540					
123		Pro	Val	Arg	Phe	Val												
124	•	545																
125	<210>	-			_													
126	<211>				3													
127	<212>						·	-12										
128	<213>				scne	rich	la co	311										
129	<400>					-a++	~~ + <i>i</i>	asts:	staa	1	ata:	t-	att	raati	taa i	taata	gcacct	60
130 131																	acgggg	
132																	ggcgac	
133																	ctgag	
134																	ttaac	
135																	attgct	
136																	gctcgc	
137																	gtggt	
138																	atactg	
139		gage	ctgtt	ag a	agcc	caaag	gg ga	accg	gggag	g tc	caaag	ggtg	ctg	gggag	gtc a	aaaaç	gcgtt	600
140																	caacc	
141																	gctaca	
142																	gagccg	
143																	acaaga	
144		gate	cagt	caa o	cgaaa	agaag	gc gt	ttcc	agaad	C CC	agata	aatc	aaaa	aagti	taa	tatco	gatgag	900

DATE: 03/10/2000 RAW SEQUENCE LISTING PAGE: TIME: 15:42:36

PATENT APPLICATION US/09/189,415

Input Set: I189415.RAW

145		ctc	ggaaa	atg (cgati	tccgt	cc ag	ggggt	tatte	g aaa	agato	gatg	ttg	tgc	gaa 1	tatag	gaagag	960
146		cag	gctaa	aag o	cagca	aggc	ga ag	gaggo	ccaaa	a caç	gcaag	gcca	ttga	aaaat	taa 1	tgcto	caggcg	1020
147		caaa	aaaa	aat a	atgai	tgaad	ca a	caago	ctaaa	a cgo	ccago	gagg	agct	gaaa	agt 1	ttcat	cgggg	1080
148		gct	ggcta	acg g	gtcti	tagt	gg c	gcati	tgati	ctt	ggtg	3 999	gaat	tggt	tgt 1	tgccg	gtcacc	1140
149		gct	gcgci	ttc a	atcga	aaaa	aa to	cagc	cggta	a gaa	acaaa	acaa	caa	caact	tac 1	tacta	caact	1200
150		acaa	acta	caa 🤉	gegea	acgta	ac g	gtaga	agaat	aaq	gcct	gcaa	ataa	ataca	acc 1	tgcad	cagggc	1260
151		aat	gtaga	ata d	cacat	tgggt	cc ag	gaaga	ataco	ate	ggaga	agca	gac	gtago	ctc 9	gatgo	gctagc	1320
152		acc	tcgt	cga (cttt	cttt	ga ca	actt	ccago	ata	aggga	accg	tgca	agaat	tac 9	gtato	gctgat	1380
153		gtta	aaaa	cat o	cgct	gcate	ga ti	cgca	aggt	g ccg	gactt	cta	att	ctaat	tac 9	gtctg	gttcag	1440
154		aata	atggg	gga a	ataca	agati	to to	gttgi	tatai	ago	cacca	attc	aaca	atcct	tac (ccggg	gatact	1500
155		act	gata	acg g	gegea	acggt	t at	tag	gaaat	c cca	agto	gcgg	ggat	tcaa	aag (cactt	atgcg	1560
156		cgt	ctgg	cgc 1	taagi	tggt	gg at	tac	gccat	gad	catgo	ggag	gati	caac	ggg 9	gggga	igtaat	1620
157		age	actq	tga a	ataci	ttcga	aa ta	aacc	cacca	a gc	gccgg	ggat	CCC	atcgi	ttt (cgtct	caaata	1680
158	agcgctgtga atacttcgaa taacccacca gcgccgggat cccatcgttt cgtctaaata tatccataat cattttattt agagggaggg aggggggaag tct														1723			
159	<210> SEQ ID NO 4																	
160	<210> SEQ 1D NO 4 <211> LENGTH: 559																	
161	<212>	TYP	E: Pl	RT														
162	<213>				sche	rich	ia co	oli										
163	<400>																	
164		Met	Pro	Ile	Gly	Asn	Leu	Gly	His	Asn	Pro	Asn	Val	Asn	Asn	Ser	Ile	
165		1			<u>-</u>	5		-			10					15		
166		Pro	Pro	Ala	Pro	Pro	Leu	Pro	Ser	Gln	Thr	Asp	Gly	Ala	Gly	Gly	Arg	
167					20					25					30			
168		Glv	Gln	Leu	Ile	Asn	Ser	Thr	Gly	Pro	Leu	Gly	Ser	Arg	Ala	Leu	Phe	
169		2		35					40					45				
170		Thr	Pro		Arq	Asn	Ser	Met	Ala	Asp	Ser	Gly	Asp	Asn	Arg	Ala	Ser	
171			50		-			55		_			60					
172		Asp	Val	Pro	Gly	Leu	Pro	Val	Asn	Pro	Met	Arg	Leu	Ala	Ala	Ser	Glu	
173		65			-		70					75					80	
174		Ile	Thr	Leu	Asn	Asp	Gly	Phe	Glu	Val	Leu	His	Asp	His	Gly	Pro	Leu	
175						85	-				90					95		
176		Asp	Thr	Leu	Asn	Arg	Gln	Ile	Gly	Ser	Ser	Val	Phe	Arg	Val	Glu	Thr	
177					100	•			_	105					110			
178		Gln	Glu	Asp	Gly	Lys	His	Ile	Ala	Val	Gly	${\tt Gln}$	Arg	Asn	Gly	Val	Glu	
179				115	•	•			120					125				
180		Thr	Ser	Val	Val	Leu	Ser	Asp	Gln	Glu	Tyr	Ala	Arg	Leu	Gln	Ser	Ile	
181			130					135					140					
182	•	Asp	Pro	Glu	Gly	Lys	Asp	Lys	Phe	Val	Phe	Thr	Gly	Gly	Arg	${\tt Gly}$	Gly	
183		145			-	_	150	_				155					160	
184		Ala	Gly	His	Ala	Met	Val	Thr	Val	Ala	Ser	Asp	Ile	Thr	Glu	Ala	Arg	•
185			•			165					170					175		
186		Gln	Arq	Ile	Leu	Glu	Leu	Leu	Glu	Pro	Lys	Gly	Thr	Gly	Glu	Ser	Lys	
187		-			180					185	-	•			190			
188		Glv	Ala	Glv		Ser	Lys	Gly	Val		Glu	Leu	Arg	Glu	Ser	Asn	Ser	
189		- 4		195			-	-	200	-				205				
190		Glv	Ala		Asn	Thr	Thr	Glu	Thr	Gln	Thr	Ser	Thr	Ser	Thr	Ser	Ser	
191		-	210					215					220					
192		Leu		Ser	Asp	Pro	Lys	Leu	Trp	Leu	Ala	Leu	Gly	Thr	Val	Ala	Thr	
193		225			-		230		-			235					240	
194			Leu	Ile	Gly	Leu	Ala	Ala	Thr	Gly	Ile	Val	Gln	Ala	Leu	Ala	Leu	
		-			_													

DATE: 03/10/2000 TIME: 15:42:36 PAGE: RAW SEQUENCE LISTING

PATENT APPLICATION US/09/189,415

Input Set: **I189415.RAW**

														-				
195						245					250					255		
196		Thr	Pro	Glu	Pro		Ser	Pro	Thr	Thr	Thr	Asp	Pro	Asp	Ala	Ala	Ala	
197					260					265		•		-	270			
198		Ser	Ala	Thr	Glu	Thr	Ala	Thr	Arq	Asp	Gln	Leu	Thr	Lys	Glu	Ala	Phe	
199				275					280	•				285				
200		Gln	Asn		Asp	Asn	Gln	Lvs	Val	Asn	Ile	Asp	Glu	Leu	Gly	Asn	Ala	
201			290					295				-	300		•			
202		Ile		Ser	Glv	Val	Leu		Asp	Asp	Val	Val		Asn	Ile	Glu	Glu	
203		305			2		310	-1-				315					320	
204			Ala	Lvs	Ala	Ala		Glu	Glu	Ala	Lvs		Gln	Ala	Ile	Glu		
205				-4-		325	1				330					335		
206		Asn	Ala	Gln	Δla		Lvs	Lvs	Tvr	Asp	-	Gln	Gln	Ala	Lvs	Arg	Gln	
207					340		-10	-1-	-1-	345					350	5	-	
208		Glu	Glu	Len		Val	Ser	Ser	Glv		Glv	Tvr	Glv	Leu		Gly	Ala	
209			014	355	_,_		502		360		0-1	-1-	1	365		2		
210		Leu	Tle		Glv	Glv	Glv	Tle	-	Va 1	Δla	Va 1	Thr		Ala	Leu	His	
211		LCu	370	Lou	017	0-7	0-7	375					380					
212		Δrα		Δsn	Gln	Pro	₩a1		Gln	Thr	Thr	Thr		Thr	Thr	Thr	Thr	
213		385	LJ 5	71011	0111	110	390	014	0111			395					400	
214			Thr	Thr	Ser	Δla		Thr	Va 1	Glu	Asn		Pro	Δla	Asn	Asn		
215					501	405	9		144		410	_,_				415		
216		Pro	Δla	Gln	Glv		Val	Δsn	Thr	Pro		Ser	Glu	Asp	Thr	Met	Glu	•
217		110	niu	U	420	71011	Vul	мьр		425	0-1	001		1101	430			
218		Ser	Ara	Δra		Ser	Met	Δla	Ser		Ser	Ser	Thr	Phe		Asp	Thr	
219		502		435		201			440					445				
220		Ser	Ser		Glv	Glv	Pro	Cvs		Ile	Ara	Met	Leu		Leu	Lys	His	
221			450		0- 1	4-7		455	5		5		460					
222		Ara		Met.	Tle	Ara	Ara		Ara	Leu	Leu	Ile		Ile	Arg	Leu	Phe	
223		465	-1-			3	470	-2-	3			475					480	
224			Ile	Trp	Glv	Ile		Ile	Ser	Val	Val		Ser	Thr	Ile	Gln	His	
225		5				485					490	- 2 -				495		
226		Pro	Pro	Ara	asp		Thr	Asp	Asn	Glv		Arq	Leu	Leu	Gly	Asn	Pro	
227					500					505					510			
228		Ser	Ala	Glv	Ile	Gln	Ser	Thr	Tyr	Ala	Arq	Leu	Ala	Leu	Ser	Gly	Gly	
229				515					520		J			525		_	-	
230		Leu	Arg	His	Asp	Met	Gly	Gly	Leu	Thr	Gly	Gly	Ser	Asn	Ser	Ala	Val	
231			530		_		_	535			_	-						
232		Asn	Thr	Ser	Asn	Asn	Pro	Pro	Ala	Pro	Gly	Ser	His	Arg	Phe	Val		
233		545					550				-	555		_				
234	<210>	SEQ	ID N	10 5					•									
235	<211>	LEN	GTH:	1460)													
236	<212>	TYPE	E: D1	IA														
237	<213>				scher	richi	ia co	oli										
238	<400>	SEQU	JENCE	S: 5														
239					etgat	gct	je te	gatto	ctcgt	gc.	agt	gata	ttcc	cgga	act	tccta	acaaat	60
240																	catgat	
241																	gaaact	
242																	ttgtt	
243		ttaa	agtga	agc a	aagaq	jttt	c ta	agctt	acag	, tc	ctto	gatc	ctga	aggt	aa a	aaaca	aattt	300
244		gtat	ttac	tg g	gaggo	cgcg	g to	gcco	aggg	cat	gcta	atgg	tcac	ggtt	gc	ttcag	gatatc	360

PAGE: 6

VERIFICATION SUMMARY
PATENT APPLICATION US/09/189,415

DATE: 03/10/2000 TIME: 15:42:36

Input Set: I189415.RAW

Line ? Error/Warning Original Text

93 W "N" or "Xaa" used: Feature required Gly Asn Ala Ile Pro Ser Gly Glu Leu Xaa A